Meridian Bioscience lance un nouveau test moléculaire pour la détection de Mycoplasma pneumoniae
April 28, 2016 02:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) a annoncé aujourd’hui qu’elle a reçu le marquage CE pour un nouveau test de diagnostic moléculaire...
Meridian Bioscience lanza una nueva prueba molecular para la detección de la bacteria Mycoplasma pneumoniae
April 28, 2016 02:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) anunció hoy que recibió la marca CE para su nueva prueba de diagnóstico molecular para la detección de...
Meridian Bioscience lancia un nuovo test molecolare per il rilevamento di Mycoplasma pneumoniae
April 28, 2016 02:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) ha annunciato oggi di aver ottenuto il marchio CE per un nuovo test diagnostico...
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
April 27, 2016 07:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma...
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
March 24, 2016 16:15 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 24, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its...
Bioline Launches New EPIK™ miRNA Select Kits
March 03, 2016 07:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 03, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the...
Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
January 27, 2016 07:30 ET
|
Meridian Bioscience Inc.
GENERAL HIGHLIGHTS CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported first quarter net revenues of $47.2 million, a...
Novo teste de malária, o illumigene® Malaria, define um novo padrão de excelência para diagnóstico
January 27, 2016 01:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- A Meridian Bioscience, Inc. (NASDAQ:VIVO) anunciou hoje que recebeu a Marca CE para o illumigene® Malaria, um teste inovador e altamente...
ชุดทดสอบโรคมาลาเรียแบบใหม่ illumigene® Malaria สร้างมาตรฐานสูงสุดใหม่สำหรับการวินิจฉัย
January 27, 2016 01:30 ET
|
Meridian Bioscience Inc.
เมืองซินซินแนติ, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) ประกาศวันนี้ว่าบริษัทได้รับเครื่องหมาย CE สำหรับ illumigene® Malaria...
Tes Malaria Baru, illumigene® Malaria, Telah Menetapkan Standar Emas Baru untuk Diagnosis
January 27, 2016 01:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan bahwa perusahaannya telah menerima Tanda CE untuk illumigene® Malaria, sebuah tes...